{'fraction_non_alphanumeric': 0.046934140802422405, 'fraction_numerical': 0.02195306585919758, 'mean_word_length': 5.849740932642487, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Blood pressure‐lowering effect of the sodium glucose co‐transporter‐2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension

This study compared the blood pressure‐lowering effect of ertugliflozin (1, 5, 25 mg), hydrochlorothiazide (HCTZ; 12.5 mg) and placebo in 194 patients with type 2 diabetes mellitus and hypertension for 4 weeks using ambulatory blood pressure monitoring. Endpoints (change from baseline to week 4) were: 24‐h mean systolic blood pressure (SBP; primary); daytime, night‐time, seated predose SBP, 24‐h, daytime, night‐time, seated predose diastolic blood pressure, 24‐h urinary glucose excretion and fasting plasma glucose (FPG; secondary). Safety and tolerability were monitored. Significant decreases in placebo‐corrected 24‐h mean SBP (−3.0 to −4.0 mmHg) were recorded for all doses of ertugliflozin (for HCTZ, this was −3.2 mmHg). Daytime, but not night‐time SBP was consistently reduced. Ertugliflozin produced dose‐dependent significant decreases in FPG and increases in urinary glucose excretion. No notable changes in plasma renin activity or urinary aldosterone were seen. The most common adverse events were urinary tract infection, genital fungal infection, upper respiratory tract infection and musculoskeletal pain.